Climb Bio financials
$11.50−2.04%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$67.9M | -$82.0M |
| Net income | -$59.9M | -$73.9M |
| Net margin | — | — |
| Diluted EPS | $-0.88 | $-1.53 |
| EBITDA | -$67.8M | -$82.0M |
| Operating cash flow | -$54.4M | -$15.6M |
| Free cash flow | -$54.5M | -$15.6M |
| Diluted shares | 67.8M | 48.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $35.7M | $87.2M |
| Short-term investments | $65.4M | $63.7M |
| Total debt | $0.00 | $0.00 |
| Total assets | $167.7M | $217.2M |
| Total liabilities | $7.3M | $5.3M |
| Shareholders' equity | $160.5M | $211.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology